Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolaj Torp

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2023
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 IndividualsMaria Kjaergaard, Katrine Prier Lindvig, Katrine Holtz Thorhauge, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2024
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort studyMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
Journal of Hepatology|March 1, 2024
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver diseaseKatrine Holtz Thorhauge, Georg Semmler, Stine Johansen, et al.
JHEP Reports : Innovation in Hepatology|March 15, 2024
Infections increase the risk of decompensation and death in patients with early alcohol-related liver diseaseStine Johansen, Simon Langkjær, Ditlev Nytoft Rasmussen, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute DecompensationLucie Simonis, Lorenz Balcar, Anna Schedlbauer, et al.
The Lancet. Gastroenterology & Hepatology|March 9, 2023
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trialMads Israelsen, Bjørn Stæhr Madsen, Nikolaj Torp, et al.
JHEP Reports : Innovation in Hepatology|December 19, 2024
Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intakeEmil Deleuran Hansen, Nikolaj Torp, Stine Johansen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 9, 2025
Steatotic Liver Disease Classification is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific TreatmentsMads Israelsen, Katrine Holtz Thorhauge, Peter Andersen, et al.
JHEP Reports : Innovation in Hepatology|January 6, 2026
<i>P</i> <i>NPLA3</i> and <i>TM6SF2</i> exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosisSophie Gensluckner, Helle Lindholm Schnefeld, Jan Embacher, et al.
The Lancet. Gastroenterology & Hepatology|September 13, 2025
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort studyNikolaj Torp, Katrine Tholstrup Bech, Helle Lindholm Schnefeld, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 28, 2023
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 IndividualsMaria Kjaergaard, Katrine Prier Lindvig, Katrine Holtz Thorhauge, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2024
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort studyMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
Journal of Hepatology|March 1, 2024
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver diseaseKatrine Holtz Thorhauge, Georg Semmler, Stine Johansen, et al.
JHEP Reports : Innovation in Hepatology|March 15, 2024
Infections increase the risk of decompensation and death in patients with early alcohol-related liver diseaseStine Johansen, Simon Langkjær, Ditlev Nytoft Rasmussen, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute DecompensationLucie Simonis, Lorenz Balcar, Anna Schedlbauer, et al.
The Lancet. Gastroenterology & Hepatology|March 9, 2023
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trialMads Israelsen, Bjørn Stæhr Madsen, Nikolaj Torp, et al.
JHEP Reports : Innovation in Hepatology|December 19, 2024
Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intakeEmil Deleuran Hansen, Nikolaj Torp, Stine Johansen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 9, 2025
Steatotic Liver Disease Classification is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific TreatmentsMads Israelsen, Katrine Holtz Thorhauge, Peter Andersen, et al.
JHEP Reports : Innovation in Hepatology|January 6, 2026
<i>P</i> <i>NPLA3</i> and <i>TM6SF2</i> exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosisSophie Gensluckner, Helle Lindholm Schnefeld, Jan Embacher, et al.
The Lancet. Gastroenterology & Hepatology|September 13, 2025
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort studyNikolaj Torp, Katrine Tholstrup Bech, Helle Lindholm Schnefeld, et al.
Pageof 5